Summary of findings for the main comparison. Summary of survival outcomes.

IP component therapy compared with IV therapy for initial management of primary epithelial ovarian cancer
Patient or population: Women with newly diagnosed epithelial ovarian cancer Settings: Hospital setting Intervention: Intraperitoneal component therapy Comparison: Intravenous therapy
Outcomes	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Overall survival	HR 0.81 (0.72 to 0.90)	2026 women (8 trials)	⊕⊕⊕⊕ high	Homogeneous data. When only the six high quality trials were considered HR = 0.80 (0.72 to 0.90) .
Progression‐free survival	HR 0.78 (0.70 to 0.86)	1311 women (5 trials)	⊕⊕⊕⊕ high	Homogeneous data.
CI: Confidence interval; HR: Hazard Ratio
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.